Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Change in Account Payables (2021 - 2025)

Aligos Therapeutics (ALGS) has disclosed Change in Account Payables for 5 consecutive years, with -$669000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Account Payables fell 295.86% year-over-year to -$669000.0, compared with a TTM value of $1.4 million through Dec 2025, up 2512.96%, and an annual FY2025 reading of $1.4 million, up 2512.96% over the prior year.
  • Change in Account Payables was -$669000.0 for Q4 2025 at Aligos Therapeutics, down from $752000.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $4.0 million in Q2 2024 and bottomed at -$4.1 million in Q3 2024.
  • Average Change in Account Payables over 5 years is $32750.0, with a median of $0.0 recorded in 2022.
  • Peak annual rise in Change in Account Payables hit 849.16% in 2024, while the deepest fall reached 1259.67% in 2024.
  • Year by year, Change in Account Payables stood at $399000.0 in 2021, then surged by 352.63% to $1.8 million in 2022, then crashed by 123.42% to -$423000.0 in 2023, then soared by 60.05% to -$169000.0 in 2024, then plummeted by 295.86% to -$669000.0 in 2025.
  • Business Quant data shows Change in Account Payables for ALGS at -$669000.0 in Q4 2025, $752000.0 in Q3 2025, and -$402000.0 in Q2 2025.